ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) presented at the Noble conference in Florida last week, and we attended their presentation. Think of IMUC as Dendrion but this time targeting brain cancer (GlioBlastoma), the same cancer that killed Ted Kennedy. This is absolutely an unmet medical need. A few points to be excited about IMUC:
- The company has now raised capital, has a modest burn rate and as such is solidly financed to the next data point.
- Lead product is ICT-107 (dendritic cell for glioblastoma - GBM, or Brain Cancer), and the Phase II trial has started.
- The Phase 1 data looks pretty remarkable. Average survival in these patients is typically about 15 months. In the Phase 1 trial IMUC has reported a median over-all survival of 38.4 months.
- Attractive valuation: $45 mln market cap, plenty of cash, Phase II trials underway, and proof of concept data in the P1 trial as well as the therapeutic area (dendritic cell approach, aka :Dendrion).
See all Daily Dose articles on IMUC.
